Journal article

Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy

M Crane, A Avihingsanon, R Rajasuriar, P Velayudham, D Iser, A Solomon, B Sebolao, A Tran, T Spelman, G Matthews, P Cameron, P Tangkijvanich, GJ Dore, K Ruxrungtham, SR Lewin

Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2014

Abstract

We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor α, and interferon γ (IFN-γ) were all associated with elevated liver enzyme levels..

View full abstract